Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
1. A method for treatment of intestinal inflammatory diseases comprising administering to a subject suffering from intestinal inflammatory disease a therapeutically effective amount of a phytocannabinoid consisting essentially of tetrahydrocannabivarin (THCV).
2. The method as claimed in claim 1 , wherein the intestinal inflammatory disease is ulcerative colitis.
3. The method as claimed in claim 1 , wherein the intestinal inflammatory disease is Crohn's disease.
4. The method as claimed in claim 1 , wherein the THCV is in a synthetic or isolated form.
5. The method as claimed in claim 1 , wherein the therapeutically effective amount of THCV is between 1 and 2000 mg.
6. The method as claimed in claim 2 , wherein the THCV is in a synthetic or isolated form.
7. The method as claimed in claim 2 , wherein the therapeutically effective amount of THCV is between 1 and 2000 mg.
8. The method as claimed in claim 3 , wherein the THCV is in a synthetic or isolated form.
9. The method as claimed in claim 3 , wherein the therapeutically effective amount of THCV is between 1 and 2000 mg.